First patient included in pediatric study IsoCOMFORT
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the first patient has been included in the company's pediatric study IsoCOMFORT (SED002) which is conducted to investigate if inhaled sedation of Sedaconda (isoflurane) via AnaConDa is a safe and more effective sedation method than intravenously administered midazolam for children under 18 years. The study is expected to be completed during the second half of 2022 and is aimed at leading to an approved pediatric indication for inhaled sedation.“AnaConDa was approved for use in children in 2019 in Europe and this study is